Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
Peer-reviewed characterization of Vivos’ PrecisionGel platform is expected to support its clinical programs, licensing discussions and future international regulatory submissions.
Rhea-AI Summary
Vivos (RDGL) announced the peer-reviewed publication of a paper characterizing its PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology, an Elsevier journal focused on drug formulation and controlled release technology.
The paper, co-developed with research partner Akina Inc., details three years of development work examining biomolecular release properties of the injectable thermogel poly(lactide-co-glycolide)-graft-(polyethylene glycol) across different concentrations and polymer compositions. PrecisionGel™ is the polymer carrier used in Vivos’ RadioGel® and IsoPet® products and is also offered as an independent universal drug delivery carrier for pharmaceutical and biomedical companies.
The company states that this publication supports clinical program credibility for its PRnT platforms, strengthens PrecisionGel™’s position as a licensing candidate, and adds to the scientific record that may aid future regulatory submissions in key international markets.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals, today announced the peer-reviewed publication of a paper describing the PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology. PrecisionGel™ is the polymer carrier component of both IsoPet® and RadioGel® and is also available independently to pharmaceutical and biomedical companies as a universal drug delivery carrier.
Publication Details
Title: “Relationship of biomolecular release properties of injectable thermogel poly(lactide-co-glycolide)-graft-(polyethylene glycol) to concentration and polymer chemical composition.”
Journal: Journal of Drug Delivery Science and Technology, an international peer-reviewed Elsevier publication covering advances in drug formulation and controlled release technology.
Article link: https://www.sciencedirect.com/science/article/pii/S1773224726008750
DOI: 10.1016/j.jddst.2026.108750
Research partner: Akina Inc., a specialty polymer research and manufacturing company that developed and produces the PrecisionGel™ polymer for Vivos Inc. The paper summarizes three years of development research at Akina characterizing the thermogel’s biomolecular release properties across a range of concentrations and polymer compositions.
Strategic Significance
Peer-reviewed publications in indexed journals are the gold standard for validating biomedical technology in the scientific and commercial community. This publication serves three strategic purposes for Vivos Inc.
Clinical program credibility. PrecisionGel™ is one of two independently patented components of RadioGel® and IsoPet®. Peer-reviewed characterization of its biomolecular release properties provides the scientific foundation that physician champions, regulatory authorities and hospital ethics committees require when evaluating a novel therapeutic platform. This publication will support the Company’s clinical programs at Mayo Clinic, Health Care Global Cancer Centre in India, and international centers of excellence as they advance.
Universal carrier licensing opportunity. PrecisionGel™ is available independently as a temperature-sensitive, injectable hydrogel carrier for a broad range of biomedical agents. A number of pharmaceutical and industrial corporations have been testing PrecisionGel™ as a universal carrier for their own agent release applications. Peer-reviewed publication of the platform’s release properties in a leading drug delivery journal significantly strengthens the technical credibility of PrecisionGel™ as a licensing candidate for these applications.
International regulatory support. Regulatory authorities in the United Kingdom, Australia, European Union, Japan and India — all priority markets in the Company’s international expansion program — place significant weight on peer-reviewed publications when evaluating novel device platforms. This publication adds to the scientific record supporting future regulatory submissions in these jurisdictions.
“Pharmaceutical and biomedical companies evaluate platform technologies through the peer-reviewed scientific literature before entering licensing or co-development discussions. This publication validates PrecisionGel™ in exactly the venue those companies read. It also strengthens the scientific foundation for our clinical programs at Mayo Clinic and internationally, where regulatory authorities and hospital ethics committees rely on the same literature to evaluate novel platforms.”
— Michael K. Korenko, Sc.D., CEO, Vivos Inc.
About Vivos Inc.
Vivos Inc. is developing Yttrium-90 Precision Radionuclide Therapy™ treatments for cancerous tumors in animals (IsoPet®) and humans (RadioGel®). The Company holds FDA Breakthrough Device designation for RadioGel® and FDA commercial authorization for IsoPet® in the United States. Both products are currently manufactured at APEL in Richland, Washington. The Company's India-based manufacturing center has received authorization from the AERB of India and is being prepared for operation.
About PrecisionGel™
PrecisionGel™ is a temperature-sensitive, injectable poly(lactide-co-glycolide)-graft-(polyethylene glycol) thermogel developed and manufactured by Akina Inc. The polymer is liquid at room temperature for ease of loading and injection, and gels at body temperature to immobilize therapeutic agents at the target site. In addition to its use as the carrier component of IsoPet® and RadioGel®, PrecisionGel™ is available independently for pharmaceutical and biomedical applications requiring controlled local agent release.
Forward-Looking Statements. This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that may cause actual results to differ materially. Timelines for regulatory approvals, clinical trial outcomes, profitability milestones and commercialization are subject to factors outside the Company's control. Vivos Inc. undertakes no obligation to update forward-looking statements except as required by law.
Contact: Mike Korenko, Sc.D., CEO, Vivos Inc., mkorenko@radiogel.com | Brad Weeks, President, brad.weeks@vivosinc.com | www.VivosInc.com
FAQ
What did Vivos (RDGL) announce about its PrecisionGel polymer platform?
Vivos announced the peer-reviewed publication of a paper describing and characterizing its PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology. The work covers biomolecular release properties across various concentrations and polymer compositions.
In which journal was the Vivos (RDGL) PrecisionGel study published?
The PrecisionGel™ study was published in the Journal of Drug Delivery Science and Technology, an international peer-reviewed Elsevier journal focused on advances in drug formulation and controlled release technology.
What is PrecisionGel and how is it used by Vivos (RDGL)?
PrecisionGel™ is a temperature-sensitive, injectable thermogel polymer carrier. It is the polymer component of Vivos’ IsoPet® and RadioGel® radionuclide therapies and is also offered independently as a universal drug delivery carrier for a broad range of biomedical agents.
Who collaborated with Vivos (RDGL) on the PrecisionGel publication and what did the research cover?
Vivos worked with Akina Inc., which developed and produces the PrecisionGel™ polymer. The peer-reviewed paper summarizes three years of development research at Akina, characterizing the thermogel’s biomolecular release properties across different concentrations and polymer chemical compositions.
Why is the PrecisionGel publication important for Vivos (RDGL) clinical programs?
The company states that peer-reviewed characterization of PrecisionGel™ provides a scientific foundation that physician champions, regulatory authorities and hospital ethics committees look for when evaluating novel therapeutic platforms, supporting ongoing clinical programs at Mayo Clinic, Health Care Global Cancer Centre in India and other centers.
How could the PrecisionGel publication affect licensing opportunities for Vivos (RDGL)?
Vivos indicates that pharmaceutical and industrial companies have been testing PrecisionGel™ as a universal carrier. Publication of its release properties in a leading drug delivery journal is expected by the company to strengthen the platform’s technical credibility as a licensing candidate for these applications.
What regulatory benefits does Vivos (RDGL) expect from the PrecisionGel publication?
The company states that regulatory authorities in markets such as the United Kingdom, Australia, EU, Japan and India place weight on peer-reviewed data. This publication adds to the scientific record that may support future regulatory submissions for Vivos’ device platforms in those regions.